Lergotrile (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name) is an ergoline derivative which acts as a dopamine receptor agonist. It was developed for the treatment of Parkinson's disease, but failed in clinical trials due to liver toxicity.[1][2]
Quick Facts Clinical data, Other names ...
Lergotrile![Thumb](//upload.wikimedia.org/wikipedia/commons/thumb/5/5f/Lergotrile_structure.png/220px-Lergotrile_structure.png) |
|
Other names | LY-79907; 2-Chloro-6-methylergoline-8β-acetonitrile |
---|
|
2-[(6aR,9S,10aR)-5-chloro-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]acetonitrile
|
CAS Number | |
---|
PubChem CID | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
ChEMBL | |
---|
CompTox Dashboard (EPA) | |
---|
|
Formula | C17H18ClN3 |
---|
Molar mass | 299.80 g·mol−1 |
---|
3D model (JSmol) | |
---|
CN1C[C@@H](C[C@H]2[C@H]1CC3=C(NC4=CC=CC2=C34)Cl)CC#N
|
InChI=1S/C17H18ClN3/c1-21-9-10(5-6-19)7-12-11-3-2-4-14-16(11)13(8-15(12)21)17(18)20-14/h2-4,10,12,15,20H,5,7-9H2,1H3/t10-,12-,15-/m1/s1 Key:JKAHWGPTNVUTNB-IXPVHAAZSA-N
|
Close
Lieberman AN, Gopinathan G, Estey E, Kupersmith M, Goodgold A, Goldstein M (February 1979). "Lergotrile in Parkinson disease: further studies". Neurology. 29 (2): 267–72. doi:10.1212/wnl.29.2.267. PMID 34808. Cunningham KA, Callahan PM, Appel JB (July 1984). "Discriminative stimulus properties of lergotrile". The Journal of Pharmacology and Experimental Therapeutics. 230 (1): 47–52. PMID 6146709.